TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics
STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy
Sirius Therapeutics Announces First Patient Dosed in Phase 2 Trial of SRSD216 for siRNA Therapy for Hyperlipoproteinemia(a)
Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium
Alpha-9 Oncology’s Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
